Donta S T, Lembke L A
Antimicrob Agents Chemother. 1985 Oct;28(4):500-3. doi: 10.1128/AAC.28.4.500.
Patients receiving gentamicin or tobramycin were studied to determine whether there were differences in the urinary excretion of N-acetyl-beta-D-glucosaminidase (NAG) between the two groups. The average daily increases in NAG excretion were significantly higher in the group receiving gentamicin. In individual patients, the best correlation with nephrotoxicity was with high initial rates of NAG excretion. If abnormally high initial rates of increase can serve as a prognosticator of nephrotoxicity, it may be possible to alter aminoglycoside therapy and to avoid renal damage.
对接受庆大霉素或妥布霉素治疗的患者进行了研究,以确定两组之间N-乙酰-β-D-氨基葡萄糖苷酶(NAG)的尿排泄是否存在差异。接受庆大霉素治疗的组中,NAG排泄的平均每日增加量显著更高。在个体患者中,与肾毒性的最佳相关性在于NAG排泄的高初始速率。如果异常高的初始增加速率可作为肾毒性的预后指标,那么有可能改变氨基糖苷类药物的治疗方案并避免肾脏损伤。